Fluvastatin

Fluvastatin
Systematic (IUPAC) name

(3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
Clinical data
Trade names	Lescol
AHFS/Drugs.com	monograph
MedlinePlus	a694010
Pregnancy category	AU: D US: X (Contraindicated)
Routes of administration	Oral
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	30%^[1]
Protein binding	>98%^[1]
Metabolism	Hepatic (CYP2C9 (75%), CYP2C8 (5%), CYP3A4 (20%))^[1]^[2]
Biological half-life	1-3 hours (capsule), 9 hours (XR)^[1]^[2]
Excretion	Faeces (95%), urine (5%)^[1]
Identifiers
CAS Number	93957-54-1^Y
ATC code	C10AA04 (WHO)
PubChem	CID 446155
IUPHAR/BPS	2951
DrugBank	DB01095^Y
ChemSpider	393587^Y
UNII	4L066368AS^Y
KEGG	D07983^Y
ChEBI	CHEBI:38565^Y
ChEMBL	CHEMBL1078^Y
Chemical data
Formula	C₂₄H₂₆FNO₄
Molar mass	411.466 g/mol
SMILES O=C(O)C[C@H](O)C[C@H](O)/C=C/c2c(c1ccccc1n2C(C)C)c3ccc(F)cc3
InChI InChI=1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19-/m1/s1^Y Key:FJLGEFLZQAZZCD-MCBHFWOFSA-N^Y
(verify)

Fluvastatin (trade names Lescol, Canef, Vastin) is a member of the statin drug class, used to treat hypercholesterolemia and to prevent cardiovascular disease.

It has also been shown to exhibit antiviral activity against hepatitis C in a study with 31 patients. This effect has been described as modest, variable, and often short-lived by the authors.^[3]

References

1 2 3 4 5 Neuvonen, PJ; Backman, JT; Niemi, M (2008). "Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.". Clinical Pharmacokinetics 47 (7): 463–74. doi:10.2165/00003088-200847070-00003. PMID 18563955.
1 2 "Lescol, Lescol XR (fluvastatin) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 18 March 2014.
↑ Bader T, Fazili J, Madhoun M; et al. (April 2008). "Fluvastatin Inhibits Hepatitis C Replication in Humans". Am. J. Gastroenterol. 103 (6): 1383–9. doi:10.1111/j.1572-0241.2008.01876.x. PMID 18410471.

Lipid modifying agents (C10)

GI tract

Cholesterol absorption inhibitors, NPC1L1	Ezetimibe SCH-48461

Bile acid sequestrants/resins (LDL)	Cholestyramine Colestipol Colestilan Colextran Colesevelam

Liver

Statins (HMG-CoA reductase, LDL)	Simvastatin^# Atorvastatin Fluvastatin Lovastatin Mevastatin Pitavastatin Pravastatin Rosuvastatin Cerivastatin^‡

Niacin and derivatives (HDL and LDL)	Niceritrol Niacin Nicofuranose Aluminium nicotinate Nicotinyl alcohol Acipimox

MTTP inhibitors (VLDL)	Dirlotapide Lomitapide Mitratapide

Blood vessels

Fibrates (PPAR)	Clofibrate^‡ Bezafibrate Aluminium clofibrate Gemfibrozil Fenofibrate Simfibrate Ronifibrate Ciprofibrate Etofibrate Clofibride Clinofibrate

CETP inhibitors (HDL)	Anacetrapib^† Dalcetrapib^§ Evacetrapib^§ Torcetrapib^§

Combinations

Other

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.